These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28300466)

  • 41. Using the time-to-event continual reassessment method in the presence of partial orders.
    Wages NA; Conaway MR; O'Quigley J
    Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses.
    Møller S
    Stat Med; 1995 May 15-30; 14(9-10):911-22; discussion 923. PubMed ID: 7569510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Stat Med; 2011 Jul; 30(17):2070-80. PubMed ID: 21344472
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continual reassessment method with regularization in phase I clinical trials.
    Li X; Ivanova A; Tian H; Lim P; Liu K
    J Biopharm Stat; 2020 Nov; 30(6):964-978. PubMed ID: 32926652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose-escalation designs in oncology: ADEPT and the CRM.
    Shu J; O'Quigley J
    Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Calibration of prior variance in the Bayesian continual reassessment method.
    Lee SM; Cheung YK
    Stat Med; 2011 Jul; 30(17):2081-9. PubMed ID: 21413054
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
    Daimon T; Zohar S; O'Quigley J
    Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Continual reassessment method (CRM)].
    Ishizuka N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A simulation-free approach to assessing the performance of the continual reassessment method.
    Braun TM
    Stat Med; 2020 Dec; 39(30):4651-4666. PubMed ID: 32939800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-finding design and benchmark for a right censored endpoint.
    Andrillon A; Chevret S; Lee SM; Biard L
    J Biopharm Stat; 2020 Nov; 30(6):948-963. PubMed ID: 33222634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents.
    Jimenez JL; Tighiouart M; Gasparini M
    Biom J; 2019 Mar; 61(2):319-332. PubMed ID: 29808507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interplay of priors and skeletons in two-stage continual reassessment method.
    Iasonos A; O'Quigley J
    Stat Med; 2012 Dec; 31(30):4321-36. PubMed ID: 22893483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implementation of a two-group likelihood time-to-event continual reassessment method using SAS.
    Salter A; Morgan C; Aban IB
    Comput Methods Programs Biomed; 2015 Oct; 121(3):189-96. PubMed ID: 26122068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimating the dose-toxicity curve in completed phase I studies.
    Iasonos A; Ostrovnaya I
    Stat Med; 2011 Jul; 30(17):2117-29. PubMed ID: 21341302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
    Labrenz J; Edelmann D; Heitmann JS; Salih HR; Kopp-Schneider A; Schlenk RF
    Pharm Stat; 2023 Mar; 22(2):236-247. PubMed ID: 36285348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium.
    Onar A; Kocak M; Boyett JM
    J Biopharm Stat; 2009; 19(3):437-55. PubMed ID: 19384687
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Some practical improvements in the continual reassessment method for phase I studies.
    Goodman SN; Zahurak ML; Piantadosi S
    Stat Med; 1995 Jun; 14(11):1149-61. PubMed ID: 7667557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
    Zang Y; Lee JJ
    Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.